CD38在骨髓增殖性肿瘤纤维化进展中单核细胞的作用
该研究通过构建NrasG12D/+Jak2V617F/+小鼠模型,发现骨髓移植后小鼠出现骨髓纤维化伴贫血和单核细胞增多,Ly6chigh单核细胞CD38表达升高导致NAD+降低,促进纤维细胞分化;人类MF患者CD14+单核细胞CD38表达也升高,靶向CD38或补充NAD+前体可抑制纤维化。
要点
- CD38在Ly6chigh单核细胞中高表达,降低NAD+水平,促进纤维细胞分化。
- MF患者单核细胞CD38表达高于对照,且与纤维化分级相关。
- 靶向CD38或补充NAD+前体可抑制纤维细胞分化并预防纤维化。
核心结论
- CD38在单核细胞中通过降低NAD+促进纤维细胞分化,参与骨髓纤维化进展。
研究设计与样本
- 研究构建可诱导的NrasG12D/+Jak2V617F/+(NJ)小鼠,移植NJ骨髓细胞后观察骨髓纤维化。
- 体外实验分析NJ受体骨髓有核细胞中CD45+CollagenI+纤维细胞及Ly6chigh单核细胞。
- 对人类MF患者和真性红细胞增多症患者的CD14+单核细胞进行CD38表达分析。
主要发现
- NJ受体小鼠出现骨髓纤维化,伴早期贫血和单核细胞增多。
- NJ受体骨髓有核细胞中CD45+CollagenI+纤维细胞增多,主要来源于Ly6chigh单核细胞。
- RNA测序显示NJ小鼠Ly6chigh单核细胞CD38表达显著升高,NAD+水平显著降低。
- 人类MF患者CD14+单核细胞CD38表达显著高于对照,且1级纤维化PV患者高于无纤维化者。
- 药理学靶向CD38或补充NAD+前体抑制体外纤维细胞分化,靶向CD38可有效预防体内纤维化发生。
临床怎么用
- CD38可作为骨髓纤维化进展的生物标志物。
- 抑制CD38可能成为MF患者的临床治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proinflammatory signaling is a hallmark of myeloproliferative neoplasms. Several studies have shown that monocytes are a major source of proinflammatory cytokines and that monocyte-derived fibrocytes play a pivotal role in the pathogenesis of myelofibrosis (MF). To further explore the role of monocytes in MF, we generated inducible NrasG12D/+Jak2V617F/+ (NJ) mice. Recipients transplanted with NJ bone marrow (BM) cells developed MF with an early onset of anemia and monocytosis. In vitro, NJ recipients' BM nucleated cells exhibited an increased quantity of CD45+CollagenI+ fibrocytes, which were mainly derived from the Ly6chigh monocytes. RNA sequencing identified a significant elevated expression of CD38 (a NAD+ hydrolase) in Ly6chigh monocytes from NJ mice, which results in a pronounced lower level of NAD+. In humans, CD14+ monocytes from patients with MF showed a significantly higher expression of CD38 than controls and monocytes from patients with polycythemia vera with grade 1 fibrosis had higher CD38 expression than those without fibrosis. Finally, boosting NAD+ via pharmacological CD38 targeting or NAD+ precursor supplementation inhibited the differentiation of fibrocytes in vitro and targeting CD38 can effectively prevent the onset of fibrosis in vivo. Collectively, our findings shed light on the role of CD38 in monocytes and suggest potential clinical applications such as the use of CD38 as a biomarker of fibrotic progression and the clinical utility of CD38 inhibition in patients with MF.
引用
- Yan Y, Liu J, Zhao S, et al. The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms. Blood. 2026. PMID: 41405487. doi:10.1182/blood.2025028703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。